# Amgen Ventures

> Amgen Ventures is a VC fund backing Biotechnology and Health Care. See 117 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 117
- Last investment: May 2026
- Lead investor: 12%
- Fund size: $100M
- Last fund: Jan 2012
- Last updated: Aug 2026
- Website: https://www.amgenbd.com/aboutamgen

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

## Contacts

5 contacts available for Amgen Ventures. Shizune tracks 2 team members at Amgen Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/amgen-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4.4M–$53M |
| Series B | $11M–$110M |
| Series C | $19M–$80M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 65 | 56% |
| Health Care | 51 | 44% |
| Therapeutics | 29 | 25% |
| Medical | 24 | 21% |
| Pharmaceutical | 15 | 13% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 29 | 25% |
| Series A | 27 | 23% |
| Series C | 15 | 13% |
| Funding Round | 8 | 7% |
| Seed | 6 | 5% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 63 | 54% |
| Canada | 3 | 3% |
| United Kingdom | 3 | 3% |
| Israel | 2 | 2% |
| Singapore | 2 | 2% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Suzanne Blaug | SVP, Global Marketing and Commercial Development | 0 | https://shizune.co/investors/profile/suzanne-blaug |
| Philip Tagari | VP Research | 3 | https://shizune.co/investors/profile/philip-tagari |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ember LifeSciences | Ember LifeSciences is a healthcare technology company that develops cold chain solutions to support the safe transport of temperature-sensitive medicines, vaccines, and biologics using proprietary temperature control systems. The company’s core offering includes the Ember Cube. This self-refrigerated and cloud-connected shipping container providescontinuous temperature monitoring, GPS tracking, and real-time data reporting to maintain drug efficacy during transit. Ember LifeSciences leverages its engineering expertise in thermal management and digital monitoring to develop modular shipping solutions that can replace traditional single-use cold chain packaging, thereby reducing waste. It works with pharmaceutical distributors, specialty pharmacies, and laboratories by enabling visibility and control over critical environmental conditions throughout distribution. The company continues to develop next-generation versions of its devices, incorporating improved insulation and configurable features to support broader supply chain use cases. |  | Series A | May 27, 2026 |  |
| EnClear Therapies | EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). |  | Venture - Series Unknown | Sep 03, 2024 |  |
| Mindset Medical | Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona. | $8M | Series A | Jun 01, 2024 |  |
| Enlaza Therapeutics | Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $100M | Series A | Apr 30, 2024 |  |
| Culmination Bio | Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform. | $10M | Series A | Nov 30, 2023 |  |
| Feldan Therapeutics | Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $16.5M | Series B | Jun 13, 2023 |  |
| Casma Therapeutics | Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs. | $46M | Series C | Nov 15, 2022 |  |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M | Series C | Oct 17, 2022 |  |
| ImmunoScape | ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution. The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, andvisualization tools to provide novel, reproducible immune profiling information. This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets. | $14M | Venture - Series Unknown | Sep 20, 2022 |  |
| BigHat Biosciences | BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatmentsfor patients suffering from today’s most challenging diseases. | $75M | Series B | Jul 20, 2022 |  |

10 of 117 investments shown.

## Co-investors
- [Alexandria Real Estate Equities](https://shizune.co/investors/profile/alexandria-real-estate-equities) — VC Fund, 11 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 11 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 10 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 10 deals together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 9 deals together
- [OVP Venture Partners](https://shizune.co/investors/profile/ovp-venture-partners) — VC Fund, 8 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Seeds Capital](https://shizune.co/investors/profile/seeds-capital) — VC Fund
- [Wavemaker Ventures](https://shizune.co/investors/profile/wavemaker-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)

## FAQ

### What does Amgen Ventures invest in?

Amgen Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 117 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Amgen Ventures's check size?

Amgen Ventures typically joins rounds of $4.4M–$53M at Series A, $11M–$110M at Series B and $19M–$80M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Amgen Ventures participates in.

### How do I contact Amgen Ventures?

Public channels for Amgen Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Amgen Ventures?

The team at Amgen Ventures includes Suzanne Blaug (SVP, Global Marketing and Commercial Development) and Philip Tagari (VP Research). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co